Press Releases April 7, 2026 08:00 PM

Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit

Lifecore Biomedical to showcase CDMO capabilities at American Biomanufacturing Summit

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
LFCR

Lifecore Biomedical, a Nasdaq-listed CDMO specializing in injectable pharmaceutical products, announced its participation at the 12th Annual American Biomanufacturing Summit in San Francisco on April 14-15, 2026. The company will present its process development and manufacturing services for injectable programs and engage with industry stakeholders.

Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
LFCR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lifecore will attend and present at the 12th Annual American Biomanufacturing Summit, highlighting its CDMO services for injectable pharmaceuticals.
  • The company has over 40 years of expertise in manufacturing injectable-grade hyaluronic acid and sterile injectable products in various formats such as syringes, vials, and cartridges.
  • Participation underlines Lifecore’s positioning as a partner for global biopharmaceutical and biotechnology companies in bringing innovations to market.

CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 12th Annual American Biomanufacturing Summit. The conference will take place April 14 - 15, 2026, in San Francisco, CA.

Details regarding Lifecore’s participation are as follows:

  • 12th Annual American Biomanufacturing Summit
    Details: Lifecore team will be present to discuss process development and manufacturing services for injectables programs.
    Booth number: 41
    Conference Dates: April 14 - 15, 2026
    Location: Hyatt Regency San Francisco Airport, San Francisco, CA

If you are interested in meeting with Lifecore during this event, please reach out to us at: cdmo@lifecore.com.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com\

Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com


Risks

  • The announcement is largely promotional with no new contracts or financial updates, which may not immediately impact revenue or earnings.
  • Market competition in the CDMO sector, particularly in sterile injectable manufacturing, remains intense, potentially limiting growth prospects.
  • Any delays or disruptions in biomanufacturing operations could impact Lifecore’s ability to fulfill client demands, posing operational risk.

More from Press Releases

CSX Unveils Commemorative Locomotives Marking America’s 250th Anniversary Jun 8, 2026 Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas Jun 8, 2026 FutureCorp Space Acquisition 1 Completes $230,000,000 Initial Public Offering Jun 8, 2026 Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference Jun 8, 2026 HII Partner Bayou Metals Launches Dedicated Manufacturing Line to Accelerate ROMULUS USV Production Jun 8, 2026